US-based development stage specialty pharmaceutical firm Tonix Pharmaceuticals (TNXP) has become a corporate partner of the American Chronic Pain Association (ACPA) as part of its efforts to help raise awareness about fibromyalgia, a central pain syndrome.
Currently, the company is currently developing TNX-102 SL, a lead clinical candidate for the treatment of fibromyalgia and post-traumatic stress disorder.
Recently, Tonix also started a BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) clinical trial, which is claimed to be the first of two expected trials for TNX-102 SL 2.8mg tablets in patients with fibromyalgia.
Tonix president and CEO Seth Lederman said the American Chronic Pain Association is dedicated to updating the public regarding the research and treatment for chronic pain in its many forms.
"Fibromyalgia is believed to affect approximately five million people in the U.S., and this syndrome is increasingly identified in people who suffer chronic pain," Lederman said.
"We are confident that this partnership will continue to bring greater recognition to fibromyalgia and provide an opportunity to report Tonix's clinical progress to those who may need it most."
